IRX4204 in combination with erlotinib to target distinct pathways in lung cancer cells.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14095
Abstract: e14095Background: IRX4204 is a Retinoid X Receptor (RXR) specific agonist (rexinoid). IRX4204 has high potency as a RXR agonist with low binding affinity to Retinoic Acid Receptors (RARs), PPAR, FX... read more here.
Keywords: pathways lung; irx4204 combination; distinct pathways; target distinct ... See more keywords